{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-027951","form_type":"8-K","ticker":"LCTX","cik":"0000876343","company_name":"Lineage Cell Therapeutics, Inc.","filed_at":"2024-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.107687+00:00","generated_at":"2026-06-05T02:12:29.802611+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lineage Cell Therapeutics reports FY2023 net loss $21.5M; cash runway into Q3 2025","bullets":["FY2023 revenue $8.9M, down 39% from $14.7M in 2022; net loss $21.5M ($0.12/sh).","Q4 2023 net loss $4.8M ($0.03/sh); total operating expenses $8.2M.","Cash $35.5M at 12/31/23 plus $13.8M net from Feb 2024 offering; funds operations into Q3 2025.","OpRegen Phase 2a for dry AMD ongoing with Roche/Genentech; OPC1 IND cleared for spinal cord trial.","Initiated hypoimmune iPSC cell line for neurology under Eterna Therapeutics collaboration."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-027951","json":"https://secwatch.observer/filing/0000950170-24-027951.json","markdown":"https://secwatch.observer/filing/0000950170-24-027951.md","text":"https://secwatch.observer/filing/0000950170-24-027951.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/876343/000095017024027951/0000950170-24-027951-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/876343/000095017024027951/lctx-20240307.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T02:12:29.802611+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ca755f9dc4f08779c27cf82b3bbf31918a539a38","claim":"Lineage Cell Therapeutics, Inc. reported three months ended December 31, 2023 results: revenue approximately $2.1 million, net income $4.8 million, EPS $0.03 per share (basic and diluted).","evidence_excerpt":"Revenues: Lineage’s revenue is generated primarily from collaboration revenues and royalties. Total revenues for the three months ended December 31, 2023 were approximately $2.1 million, a net increase of $0.2 million as compared to $1.9 million for the same period in 2022. Operating Expenses: Operating expenses are comprised of research and development (“R&D”)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/876343/000095017024027951/0000950170-24-027951-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended December 31, 2023"},{"label":"Revenue","value":"approximately $2.1 million"},{"label":"Net income","value":"$4.8 million"},{"label":"EPS","value":"$0.03 per share (basic and diluted)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"dd30cf538c6f7f4368b90816985b9308edafc6be","claim":"Lineage Cell Therapeutics, Inc. reported year ended December 31, 2023 results: revenue $8.9 million.","evidence_excerpt":"Total revenues for the year ended December 31, 2023 were $8.9 million, a decrease of $5.8 million as compared to $14.7 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/876343/000095017024027951/0000950170-24-027951-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2023"},{"label":"Revenue","value":"$8.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}